News for AXGT Stock

Axovant Gene Therapies Announces Name Change to Sio Gene Therapies Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020 Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020 Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences" Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020 Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 Gangliosidosis Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020 Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference